Open AccessImmunotherapy approaches targeting neuroblastoma
Author(s) -
Rosa Nguyen,
Carol J. Thiele
Publication year - 2020
Publication title -
current opinion in pediatrics, with evaluated medline/current opinion in pediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 87
eISSN - 1080-8116
pISSN - 1040-8703
DOI - 10.1097/mop.0000000000000982
Subject(s) - medicine , immunotherapy , neuroblastoma , clinical trial , minimal residual disease , monoclonal antibody , immune system , cancer immunotherapy , disease , limiting , oncology , immunology , antibody , mechanical engineering , biology , leukemia , engineering , genetics , cell culture
In the era of immune-oncology, a breakthrough in the field of pediatric solid tumor research has been the demonstration that immunotherapy for patients with high-risk neuroblastoma improves the event-free and overall survival. Immunotherapeutic approaches including a monoclonal antibody targeting the cell surface glycosphingolipid disialoganglioside and cytokines successfully eliminate minimal residual disease.